Hamburg - Delayed Quote EUR

Certara, Inc. (700.HM)

11.26

-0.16

(-1.40%)

At close: 5:25:18 PM GMT+2

Certara, Inc. (CERT) Q1 Earnings and Revenues Beat Estimates

Certara (CERT) delivered earnings and revenue surprises of 7.69% and 0.01%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 1 hour ago

CERT
Certara Reports First Quarter 2025 Financial Results

Reiterates Full Year 2025 Financial GuidanceRADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal year 2025. First Quarter Highlights: Revenue was $106.0 million, compared to $96.7 million in the first quarter of 2024, representing growth of 10%. Software revenue was $46.4 million, compared to $39.3 million in the first quarter of 2024, representing growt

GlobeNewswire 3 hours ago

CERT
Certara to Participate in Upcoming Investor Conferences

RADNOR, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: BofA Securities 2025 Healthcare ConferenceDate and Time: Tuesday, May 13 at 3:40 p.m. PT William Blair 45th Annual Growth Stock ConferenceDate and Time: Wednesday, June 4 at 12:40 p.m. CT Live webcasts for each of the conferences will be available on Certara’s investor rela

GlobeNewswire 6 days ago

CERT
Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 6 days ago

SRPT

CERT
Certara, Inc. (CERT) Earnings Expected to Grow: Should You Buy?

Certara (CERT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 7 days ago

CERT

EXAS
Will Certara (CERT) Beat Estimates Again in Its Next Earnings Report?

Certara (CERT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks 19 days ago

CERT
Why Certara Inc. (CERT) Skyrocketed On Monday?

We recently published a list of Biotech Stocks Dominate Monday’s Top 10 Gainers. In this article, we are going to take a look at where Certara Inc. (NASDAQ:CERT) stands against other biotech stocks that dominate Monday’s top gainers. The stock market kicked off the shortened trading week on a positive note, with Wall Street’s major […]

Insider Monkey 20 days ago

CERT

^GSPC
Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

New offering provides strategic guidance and AI-enabled biosimulation to navigate FDA’s Roadmap to Reducing Animal Testing in Preclinical Safety StudiesRADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of its Non-Animal Navigator™ solution designed to help biopharmaceutical companies lead the transition ignited by the FDA’s Roadmap to Reducing Animal Testing in Preclinical Safety Studies. T

GlobeNewswire 21 days ago

CERT
Certara Reports Preliminary First Quarter 2025 Financial Results; Announces $100 Million Share Repurchase Authorization

Reiterates Full-Year 2025 GuidanceArsenal Capital Partners agrees to a one-year lock-up RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced expected revenue and bookings for the first quarter of 2025 based upon a preliminary review of first quarter results. Additionally, the company announced that its Board of Directors has authorized a stock repurchase program under which the company may repurchase up

GlobeNewswire 21 days ago

CERT
Why Certara Inc. (CERT) Soared Last Week?

We recently published a list of 10 Firms Defy Market Slump, Record Double-Digit Gains Last Week. In this article, we are going to take a look at where Certara Inc. (NASDAQ:CERT) stands against other firms that defied the market slump and recorded double-digit gains last week. The stock market may have taken a beating for […]

Insider Monkey 23 days ago

CERT

^GSPC
Why Certara Inc. (CERT) Surged On Friday?

We recently published a list of Gold, Biopharma Firms Dominate Friday’s 10 Top Performing Stocks. In this article, we are going to take a look at where Certara Inc. (NASDAQ:CERT) stands against other Friday’s top performing stocks. The stock market finished the trading week on a positive note, wiping out earlier losses on Friday, as […]

Insider Monkey 23 days ago

CERT

^GSPC
Certara (CERT) Soars 8.0%: Is Further Upside Left in the Stock?

Certara (CERT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks 24 days ago

CERT
Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities

Updates strengthen Certara’s position as a leader of PBPK modeling in drug development to advance regulatory decision-makingRADNOR, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has released a new version of the Simcyp™ Simulator for physiologically-based pharmacokinetic (PBPK) modeling. Simcyp PBPK models describe and predict the behavior of drugs in different body tissues. The latest version includes numerous advanceme

GlobeNewswire last month

CERT
At US$9.91, Is Certara, Inc. (NASDAQ:CERT) Worth Looking At Closely?

Certara, Inc. ( NASDAQ:CERT ), is not the largest company out there, but it saw significant share price movement during...

Simply Wall St. last month

CERT
Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last?

Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks last month

ARVN

CERT
Certara, Inc. (CERT): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts

We recently compiled a list of the 10 Cash-Rich Small Cap Stocks To Invest In According To Analysts. In this article, we are going to take a look at where Certara, Inc. (NASDAQ:CERT) stands against the other cash-rich small cap stocks. Small-cap stocks in the US have been under pressure, with the Russell small cap index […]

Insider Monkey last month

CERT
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

McKemey joins Certara to accelerate growth of its strategic drug development solutionsRADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President of Drug Development Solutions, effective March 3rd, 2025. In this role, McKemey will lead Certara's global team of drug development scientists. Adrian joins Certara after serving as head of Enterprise Transformatio

GlobeNewswire last month

CERT
Q4 2024 Certara Inc Earnings Call

Q4 2024 Certara Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

CERT
Certara Inc (CERT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions

Certara Inc (CERT) reports a robust 14% increase in fourth-quarter revenue, driven by software growth and strategic acquisitions, while navigating market challenges.

GuruFocus.com 2 months ago

CERT
Certara, Inc. (CERT) Surpasses Q4 Earnings and Revenue Estimates

Certara (CERT) delivered earnings and revenue surprises of 15.38% and 0.68%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

CERT

Performance Overview

Return	700.HM	S&P 500 (^GSPC)
YTD	+12.33%	-3.93%
1-Year	-30.42%	+10.19%
3-Year	-37.82%	+36.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Certara, Inc. (700.HM)

Certara, Inc. (CERT) Q1 Earnings and Revenues Beat Estimates

Certara Reports First Quarter 2025 Financial Results

Certara to Participate in Upcoming Investor Conferences

Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth

Certara, Inc. (CERT) Earnings Expected to Grow: Should You Buy?

Will Certara (CERT) Beat Estimates Again in Its Next Earnings Report?

Why Certara Inc. (CERT) Skyrocketed On Monday?

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

Certara Reports Preliminary First Quarter 2025 Financial Results; Announces $100 Million Share Repurchase Authorization

Why Certara Inc. (CERT) Soared Last Week?

Why Certara Inc. (CERT) Surged On Friday?

Certara (CERT) Soars 8.0%: Is Further Upside Left in the Stock?

Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities

At US$9.91, Is Certara, Inc. (NASDAQ:CERT) Worth Looking At Closely?

Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last?

Certara, Inc. (CERT): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts

Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

Q4 2024 Certara Inc Earnings Call

Certara Inc (CERT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions

Certara, Inc. (CERT) Surpasses Q4 Earnings and Revenue Estimates

Performance Overview